دورية أكاديمية
[Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease].
| العنوان: | [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. |
|---|---|
| المؤلفون: | Li W; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou 450003, China. liwei71@126.com, Zhao JH, Sun SG, Zhang JW, Suo AQ, Ma MM |
| المصدر: | Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2011 Feb 01; Vol. 91 (5), pp. 301-3. |
| نوع المنشور: | English Abstract; Journal Article; Randomized Controlled Trial |
| اللغة: | Chinese |
| بيانات الدورية: | Publisher: Zhonghua yi xue hui Country of Publication: China NLM ID: 7511141 Publication Model: Print Cited Medium: Print ISSN: 0376-2491 (Print) Linking ISSN: 03762491 NLM ISO Abbreviation: Zhonghua Yi Xue Za Zhi Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Beijing : Zhonghua yi xue hui Original Publication: Beijing : Zhonghua yi xue hui. |
| مواضيع طبية MeSH: | Antiparkinson Agents/*therapeutic use , Cognition Disorders/*drug therapy , Memantine/*therapeutic use , Parkinson Disease/*drug therapy, Aged ; Antiparkinson Agents/adverse effects ; Female ; Humans ; Male ; Memantine/adverse effects ; Middle Aged ; Treatment Outcome |
| مستخلص: | Objective: To study the effects of memantine on cognitive and motor impairment in patients with Parkinson's disease (PD). Methods: A total of 55 PD patients complicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group (n = 28) received memantine (20 mg/d) while those in the control group (n = 27) conventional antiparkinsonian drug therapy alone. The cognitive and motor evaluations were assessed at pre-treatment and 12, 24 weeks post-treatment by clinical assessment, rating scales and neuropsychological tests. Results: At week 24 the patients in the memantine group had better MMSE (22.8 ± 1.8), ADAS-cog (18.6 ± 2.3), and UPDRS-III (34.6 ± 4.2) scales scores than those taking placebo MMSE (18.5 ± 1.7), ADAS-cog (21.9 ± 2.4), and UPDRS-III (41.2 ± 4.0). Patients treated with memantine had better improvement on the MMSE (P < 0.05), ADAS-cog (P < 0.05), and UPDRS-III (P < 0.05) scales compared with the control group by the end of study week 24. Conclusion: Memantine may improve the cognitive and motor impairments of PD. And it is both safe and well-tolerated. |
| المشرفين على المادة: | 0 (Antiparkinson Agents) W8O17SJF3T (Memantine) |
| تواريخ الأحداث: | Date Created: 20110323 Date Completed: 20111115 Latest Revision: 20131121 |
| رمز التحديث: | 20231215 |
| PMID: | 21419002 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0376-2491 |
|---|